ORI
TVTX icon

Oak Ridge Investments’s Travere Therapeutics TVTX Stock Holding History

Oak Ridge Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
52,234
-15,089
-22% -$669K 0.17% 84
2026
Q1 		$2M Buy
67,323
+940
+1% +$28.1K 0.13% 94
2025
Q4 		$2.54M Sell
66,383
-1,849
-3% -$60.1K 0.15% 77
2025
Q3 		$1.63M Buy
68,232
+16,755
+33% +$315K 0.11% 105
2025
Q2 		$762K Sell
51,477
-2,593
-5% -$43K 0.05% 128
2025
Q1 		$969K Buy
54,070
+1,471
+3% +$29.9K 0.08% 115
2024
Q4 		$916K Sell
52,599
-2,740
-5% -$48.5K 0.07% 120
2024
Q3 		$774K Sell
55,339
-2,245
-4% -$23.4K 0.07% 125
2024
Q2 		$473K Sell
57,584
-8,342
-13% -$56.2K 0.05% 136
2024
Q1 		$508K Buy
65,926
+7,744
+13% +$65.3K 0.05% 135
2023
Q4 		$523K Sell
58,182
-16,132
-22% -$117K 0.06% 137
2023
Q3 		$664K Sell
74,314
-2,301
-3% -$32.5K 0.08% 131
2023
Q2 		$1.18M Sell
76,615
-3,435
-4% -$62.5K 0.15% 116
2023
Q1 		$1.8M Sell
80,050
-3,927
-5% -$83.5K 0.24% 102
2022
Q4 		$1.77M Sell
83,977
-3,091
-4% -$65.5K 0.26% 103
2022
Q3 		$2.15M Sell
87,068
-198
-0.2% -$5.12K 0.33% 96
2022
Q2 		$2.11M Sell
87,266
-5,387
-6% -$135K 0.31% 96
2022
Q1 		$2.39M Sell
92,653
-56,424
-38% -$1.5M 0.27% 95
2021
Q4 		$4.63M Sell
149,077
-2,762
-2% -$77.8K 0.39% 80
2021
Q3 		$3.68M Sell
151,839
-3,129
-2% -$57.5K 0.32% 98
2021
Q2 		$2.26M Sell
154,968
-8,403
-5% -$166K 0.2% 113
2021
Q1 		$4.08M Buy
163,371
+41,295
+34% +$1.14M 0.38% 96
2020
Q4 		$3.33M Sell
122,076
-31,777
-21% -$742K 0.29% 106
2020
Q3 		$2.84M Sell
153,853
-9,951
-6% -$193K 0.22% 113
2020
Q2 		$3.34M Sell
163,804
-18,313
-10% -$292K 0.28% 102
2020
Q1 		$2.66M Buy
182,117
+1,648
+0.9% +$24.8K 0.27% 100
2019
Q4 		$2.56M Sell
180,469
-35,825
-17% -$458K 0.19% 112
2019
Q3 		$2.51M Sell
216,294
-28,987
-12% -$479K 0.19% 109
2019
Q2 		$4.93M Sell
245,281
-18,315
-7% -$362K 0.34% 99
2019
Q1 		$5.96M Sell
263,596
-17,523
-6% -$387K 0.38% 97
2018
Q4 		$6.36M Sell
281,119
-13,723
-5% -$341K 0.46% 81
2018
Q3 		$8.47M Sell
294,842
-35,012
-11% -$1M 0.47% 84
2018
Q2 		$8.99M Sell
329,854
-29,691
-8% -$791K 0.51% 86
2018
Q1 		$8.04M Sell
359,545
-132,361
-27% -$3.15M 0.45% 85
2017
Q4 		$10.4M Sell
491,906
-247,556
-33% -$5.66M 0.49% 77
2017
Q3 		$18.4M Sell
739,462
-283,409
-28% -$6.24M 0.75% 54
2017
Q2 		$19.8M Buy
1,022,871
+503,428
+97% +$9.13M 0.63% 63
2017
Q1 		$9.59M Sell
519,443
-93,683
-15% -$1.83M 0.32% 81
2016
Q4 		$11.6M Buy
+613,126
New +$12.5M 0.38% 68

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Oak Ridge Investments's TVTX Position: Q2 2026 in Review

Oak Ridge Investments reduced its Travere Therapeutics (TVTX) stake by 22% in Q2 2026, selling an estimated $669K and leaving 52,234 shares worth $2.97M. The position accounts for 0.17% of the portfolio, ranked #84.

Oak Ridge Investments first reported a position in TVTX in Q4 2016 and has held it in 39 quarters since. The position peaked at $19.8M in Q2 2017. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Oak Ridge Investments held 52,234 shares of Travere Therapeutics worth $2.97M as of Q2 2026.
  • Oak Ridge Investments sold 15,089 Travere Therapeutics shares in Q2 2026, an estimated $669K.
  • Travere Therapeutics made up 0.17% of Oak Ridge Investments's portfolio in Q2 2026, its #84 holding.
  • Oak Ridge Investments first reported a position in Travere Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Oak Ridge Investments's Travere Therapeutics position peaked at $19.8M in Q2 2017.
  • 35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Oak Ridge Investments's 13F filing for Q2 2026, filed 21 Jul 2026.